FBT delivered 52.4% returns over one year but with deeper drawdowns, while XLV's diversified approac

Amova Asset Management Americas Inc. lessened its stake in shares of Veracyte, Inc. (NASDAQ: VCYT) b

Artisan Mid Cap Fund portfolio generated strong absolute returns and outpaced the Russell Midcap® Gr

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys

Wall Street analysts initiated coverage on various top stocks, including VCYT, UMAC, FISN, LTRX, and

Piper Sandler analyst David Westenberg initiates coverage on Veracyte (NASDAQ:VCYT) with a Overwe

Canaccord Genuity analyst Kyle Mikson maintains Veracyte (NASDAQ:VCYT) with a Hold and raises the

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagno

Morgan Stanley analyst Tejas Savant maintains Veracyte (NASDAQ:VCYT) with a Underweight and raise

Veracyte (VCYT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about

Chief Accounting Officer Jonathan Wygant sold 24,000 shares on May 22, 2026, generating a transactio

VCYT's 117% stock surge is driven by durable growth plans, Afirma demand, TrueMRD progress, internat

Guggenheim analyst Subbu Nambi maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price t

A director of Veracyte reported selling 3,729 shares for a transaction value of approximately $197K

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investi

On Wednesday, June 10, 2026, Ark Invest sold $7.8M in Robinhood shares Wednesday while adding 141,50

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investi

Explore how these two healthcare ETFs differ in diversification, sector focus, and portfolio concent

Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock?

Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and

Needham analyst Mike Matson maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price targ

On the heels of the landmark [url="]OPTIMA trial[/url] readout presented at the ASCO Annual Meeting,

On the heels of the landmark OPTIMA trial readout presented at the ASCO Annual Meeting, Veracyte, In

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #BreastCancer--Veracyte Announces Commercial

[url="]Veracyte, Inc.[/url] (Nasdaq: VCYT), a leading cancer diagnostics company, today announced re

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #ASCO26--ENZAMET Trial Shows Veracyte's Decip

Highest level of prospective evidence supports test-directed chemotherapy decisions in broadest high

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #ASCO26--OPTIMA Trial Delivers Practice-Chang

Veracyte is evolving into a multi-cancer clinical decision-making platform, leveraging evidence, pay

Canaccord Genuity analyst Kyle Mikson maintains Veracyte (NASDAQ:VCYT) with a Hold and raises the

Dow Jones up 500 points, DaVita Inc (DVA) shares rise after better-than-expected earnings and raised

Veracyte (NASDAQ:VCYT) raises FY2026 sales outlook from $570.000 million-$582.000 million to $582.00

Veracyte (NASDAQ:VCYT) reported quarterly earnings of $0.52 per share which beat the analyst consens

Canaccord Genuity analyst Kyle Mikson maintains Veracyte (NASDAQ:VCYT) with a Hold and lowers the

Jefferies analyst Tycho Peterson initiates coverage on Veracyte (NASDAQ:VCYT) with a Buy rating a

Guggenheim analyst Subbu Nambi maintains Veracyte (NASDAQ:VCYT) with a Buy and lowers the price t

Morgan Stanley analyst Tejas Savant maintains Veracyte (NASDAQ:VCYT) with a Underweight and lower

Needham analyst Mike Matson maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price targ

Veracyte (NASDAQ:VCYT) affirms FY2026 sales outlook from $570.000 million-$582.000 million to $570.0

Veracyte (NASDAQ:VCYT) reported quarterly earnings of $0.53 per share which beat the analyst consens